Skip to main content
Clinical Trials/CTRI/2021/09/036767
CTRI/2021/09/036767
Not Yet Recruiting
Phase 3

A prospective study to investigate peri-operative management of patients with severe haemophilia A who are on Emicizumab therapy and are undergoing elective major surgeries - Not applicable

Roche Products India Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs
Sponsor
Roche Products India Pvt Ltd
Status
Not Yet Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \>2 years \<60 years, severe haemophilia A with or without inhibitor, elective major surgery for any indication except neurosurgical or invasive ophthalmic procedures.

Exclusion Criteria

  • Emergency surgery, severe organ dysfunction, coagulopathy (DIC) requiring multiple blood product support, patients requiring antiplatelet agents, patients on any other on\-going trial, history of previous thromboembolic episode, previous hypersensitivity to any of the study drugs.

Outcomes

Primary Outcomes

Not specified

Similar Trials